Methotrexate treatment has greatly improved outcome for most jLS patients but a substantial
portion have refractory cutaneous and/or extracutaneous disease. Treatment response …

Localized scleroderma (LS), also known as morphea, is an idiopathic inflammatory and
sclerosing disorder affecting the skin and subcutaneous structures. 1, 2 Although skin …

Objective The aim of this study was to evaluate factors associated with extracutaneous
involvement (ECI) in juvenile localized scleroderma (jLS). Methods A prospective …

Objective The objective was to develop consensus treatment plans (CTPs) for patients with
refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease …

Objective To evaluate the safety and efficacy of abatacept treatment for refractory juvenile
localized scleroderma (jLS) in a retrospective study. Methods A multicentre cohort study was …

Background Juvenile localized scleroderma (JLS) is a rare pediatric disease characterized
by inflammation and skin thickening. JLS is associated with deep tissue and extracutaneous …

Juvenile localized scleroderma is characterised by inflammation which drives fibrosis in skin
and soft tissues. The more severe subtypes of localized scleroderma such as linear and …

Suzanne C. Li, MD, PhD1, Kathleen M. O'Neil, MD2, and Gloria C. Higgins, MD, PhD3
Juvenile localized scleroderma, also called morphea, is a chronic autoimmune and fibrosing …

We investigated the ability of a panel of immune-related cytokines and chemokines to
predict the disease activity state in localized scleroderma (LS) subjects followed …

Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly
associated with poor outcome, including contractures, hemi-atrophy, uveitis, and seizures …